Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported third-quarter 2026 net product revenue of approximately $17.2 million, a sharp increase from $3.3 million in the prior-year period, according to the company’s financial results for the quarter ended Sept. 30, 2026. The revenue total included $15 million from TONMYA, the company’s recently approved flagship medicine for fibromyalgia, representing a 37% increase over the second quarter.
Total prescriptions for TONMYA rose 28% quarter over quarter to 16,375, while new prescriptions increased 17% and refills climbed 56%. Coverage for the treatment expanded to approximately 166 million lives, and Tonix increased its sales force to roughly 150 representatives. The company noted that TONMYA is the first new treatment for fibromyalgia in more than 15 years, a factor that may explain the strong early uptake and could signal a meaningful commercial opportunity in a condition with high unmet need.
Despite the revenue growth, Tonix reported a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with a loss of $32 million, or $3.59 per share, a year earlier. The company ended the quarter with approximately $163 million in cash and cash equivalents and expects its resources, together with approximately $1.5 million in subsequent equity financing proceeds, to fund operations into early third-quarter 2027. That cash runway may reassure investors about near-term funding stability even as losses widen.
Tonix is also advancing its clinical pipeline. The company continues the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, the planned Phase 2 TRAIL study of TNX-4800 for Lyme disease prevention and an investigator-initiated Phase 2 study of TNX-1500 for kidney transplant rejection prevention. The latter two studies are expected to begin in the first quarter of 2027, with the TNX-4800 study pending final U.S. Food and Drug Administration agreement on its protocol. These programs could diversify Tonix’s revenue base beyond its commercial CNS products, which also include acute migraine treatments Zembrace SymTouch and Tosymra.
For readers tracking the company’s progress, the full press release is available at https://ibn.fm/xRQdn, and the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. Additional coverage of Tonix Pharmaceuticals (NASDAQ: TNXP) is published by TinyGems, a communications platform within the Dynamic Brand Portfolio at IBN.
The implications for investors and the broader biotech sector are twofold. On one hand, TONMYA’s 37% sequential sales growth and expanding payer coverage suggest that Tonix’s commercial launch is gaining traction, which could support further revenue gains if prescription trends continue. On the other hand, the widening net loss and the need for additional financing highlight the cash-intensive nature of commercial-stage drug development. Tonix’s ability to fund operations into early third-quarter 2027 will depend on maintaining that momentum while advancing its pipeline candidates through costly clinical trials. For patients, the continued development of TNX-102 SL for major depressive disorder and TNX-4800 for Lyme disease prevention could eventually offer new options in areas of significant unmet medical need, though the company cautions that these product candidates are investigational and their efficacy and safety have not been established.
